Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer’s Disease Pathology Between Three Independent Assay Platforms

Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study

(2016) Antoine Leuzy et al.   BRAIN

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography

(2016) Sebastian Palmqvist et al.   BRAIN

Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements

(2016) Maria Bjerke et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer’s Disease with Updated Protocols

(2016) Min Jeong Wang et al.   JOURNAL OF ALZHEIMERS DISEASE

NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers

(2016) Stephanie J.B. Vos et al.   NEUROBIOLOGY OF AGING

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

(2016) Clifford R. Jack et al.   NEUROLOGY

Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis

(2016) Niklas Mattsson et al.   Nature Communications

Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis

(2016) Y. Iturria-Medina et al.   Nature Communications

Drug development in Alzheimer’s disease: the path to 2025

(2016) Jeffrey Cummings et al.   Alzheimers Research & Therapy

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease

(2016) Shorena Janelidze et al.   Annals of Clinical and Translational Neurology

Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research

(2015) Sid E. O'Bryant et al.   Alzheimers & Dementia

Alzheimer’s disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology

(2015) Alan Rembach et al.   Alzheimers Research & Therapy

Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease

(2015) Katarzyna Adamczuk et al.   Alzheimers Research & Therapy

FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic mice

(2015) Behrooz H Yousefi et al.   EJNMMI Research

The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

(2014) José Luis Molinuevo et al.   Alzheimers & Dementia

A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease

(2014) Eric Karran et al.   ANNALS OF NEUROLOGY

Phosphorylated Tau-Aβ 42 Ratio as a Continuous Trait for Biomarker Discovery for Early-Stage Alzheimer’s Disease in Multiplex Immunoassay Panels of Cerebrospinal Fluid

(2014) Oscar Harari et al.   BIOLOGICAL PSYCHIATRY

Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers

(2014) S. M. Landau et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Comparison of Two Analytical Platforms for CSF Biomarkers of Alzheimer’s Disease

(2014) Jose Antonio Monge-Argilés et al.   Biomed Research International

Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42

(2014) Sebastian Palmqvist et al.   JAMA Neurology

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI

(2013) Jon B. Toledo et al.   ACTA NEUROPATHOLOGICA

CSF biomarker variability in the Alzheimer's Association quality control program

(2013) Niklas Mattsson et al.   Alzheimers & Dementia

Alzheimer Disease Biomarker Testing in Cerebrospinal Fluid: A Method to Harmonize Assay Platforms in the Absence of an Absolute Reference Standard

(2013) H. M. Vanderstichele et al.   CLINICAL CHEMISTRY

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

(2013) Victor L Villemagne et al.   LANCET NEUROLOGY

Development and Advanced Validation of an Optimized Method for the Quantitation of Aβ42 in Human Cerebrospinal Fluid

(2012) Valerie C. Cullen et al.   AAPS Journal

Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer’s disease study

(2012) Wesley Jongbloed et al.   Alzheimers & Dementia

Accelerated cortical atrophy in cognitively normal elderly with high  -amyloid deposition

(2012) G. Chetelat et al.   NEUROLOGY

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

(2011) Hugo Vanderstichele et al.   Alzheimers & Dementia

Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of β-Amyloid 1-42, Total tau, and P-tau181 for Identifying Alzheimer Disease Amyloid Plaque Pathology

(2011) Anne M. Fagan   ARCHIVES OF NEUROLOGY

Phase III trial results for the amyoid PET imaging agent Florbetapir F 18 ( 18 F-AV-45): imaging to histopathologic correlations in an end-of-life human subject study

(2010) Christopher M. Clark et al.   Alzheimers & Dementia

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial

(2010) Rik Vandenberghe et al.   ANNALS OF NEUROLOGY

In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18)

(2010) D. F. Wong et al.   JOURNAL OF NUCLEAR MEDICINE

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

(2010) Christopher C. Rowe et al.   NEUROBIOLOGY OF AGING

The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease

(2009) Kathryn A Ellis et al.   INTERNATIONAL PSYCHOGERIATRICS